Robert S Rosenson

Summary

Publications

  1. ncbi request reprint Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia
    Robert S Rosenson
    Preventive Cardiology Center, Department of Medicine, Division of Cardiology, Northwestern University, The Feinberg School of Medicine, Galter Pavilion, Suite 11 120, 201 East Huron Street, Chicago, IL 60611, USA
    Atherosclerosis 185:327-30. 2006
  2. ncbi request reprint Short-term reduction in bone markers with high-dose simvastatin
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Departments of Medicine and Preventive Medicine, Northwestern University, Feinberg School of Medicine, 301 E Huron Street, Galter Pavilion, Chicago, IL 60611, USA
    Osteoporos Int 16:1272-6. 2005
  3. ncbi request reprint Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Lab Clin Med 145:83-7. 2005
  4. doi request reprint Management of non-high-density lipoprotein abnormalities
    Robert S Rosenson
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of New York, Downstate, Brooklyn, NY, USA
    Atherosclerosis 207:328-35. 2009
  5. ncbi request reprint Statins: can the new generation make an impression?
    Robert S Rosenson
    Northwestern University, Preventive Cardiology Center, The Feinberg School of Medicine, 201 E Huron Street, Galter Pavilion, Suite 11 120, Chicago, IL 60611, USA
    Expert Opin Emerg Drugs 9:269-79. 2004
  6. doi request reprint Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients
    Robert S Rosenson
    Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Obesity (Silver Spring) 17:504-9. 2009
  7. doi request reprint Biomarkers, atherosclerosis and cardiovascular events
    Robert S Rosenson
    Department of Medicine, University of Michigan, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Drive, Lobby A, Ann Arbor, MI 48106, USA
    Expert Rev Cardiovasc Ther 6:619-22. 2008
  8. ncbi request reprint Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, Chicago, IL, USA
    Am Heart J 151:556-63. 2006
  9. pmc Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial
    Michael Davidson
    Radiant Research, Chicago, IL 60610, USA
    Cardiovasc Drugs Ther 26:349-58. 2012
  10. doi request reprint Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production
    Robert S Rosenson
    Department of Medicine, SUNY Downstate, Brooklyn, NY 11203, USA
    Cardiovasc Drugs Ther 23:289-94. 2009

Detail Information

Publications39

  1. ncbi request reprint Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia
    Robert S Rosenson
    Preventive Cardiology Center, Department of Medicine, Division of Cardiology, Northwestern University, The Feinberg School of Medicine, Galter Pavilion, Suite 11 120, 201 East Huron Street, Chicago, IL 60611, USA
    Atherosclerosis 185:327-30. 2006
    ..The effect of colesevelam HCl on LDL particle number and particle size has not been previously published. LDL particle number and particle size were measured by NMR spectroscopy...
  2. ncbi request reprint Short-term reduction in bone markers with high-dose simvastatin
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Departments of Medicine and Preventive Medicine, Northwestern University, Feinberg School of Medicine, 301 E Huron Street, Galter Pavilion, Chicago, IL 60611, USA
    Osteoporos Int 16:1272-6. 2005
    ..Short-term use of high-dose simvastatin lowers the level of the serum bone marker bone-specific alkaline phosphatase, which suggests the possibility of reduced bone turnover...
  3. ncbi request reprint Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Lab Clin Med 145:83-7. 2005
    ..46, P = .0056) in statin-treated subjects. Statin therapy reduced MCP-1 production in the whole blood of human subjects and these changes were correlated with improvement in LDL oxidative resistance...
  4. doi request reprint Management of non-high-density lipoprotein abnormalities
    Robert S Rosenson
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of New York, Downstate, Brooklyn, NY, USA
    Atherosclerosis 207:328-35. 2009
    ..Improvement in lipid control and reduction in atherogenic risk could be anticipated to translate to benefits in clinical outcomes...
  5. ncbi request reprint Statins: can the new generation make an impression?
    Robert S Rosenson
    Northwestern University, Preventive Cardiology Center, The Feinberg School of Medicine, 201 E Huron Street, Galter Pavilion, Suite 11 120, Chicago, IL 60611, USA
    Expert Opin Emerg Drugs 9:269-79. 2004
    ..Results of a number of outcome studies with rosuvastatin are expected over the next 5 years, which will contribute to the evidence base for statin therapy and cardiovascular disease prevention...
  6. doi request reprint Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients
    Robert S Rosenson
    Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Obesity (Silver Spring) 17:504-9. 2009
    ..Changes in adiponectin were significantly and inversely associated with changes in multiple inflammatory markers. These data suggest that adiponectin may contribute to the anti-inflammatory effects of fenofibrate...
  7. doi request reprint Biomarkers, atherosclerosis and cardiovascular events
    Robert S Rosenson
    Department of Medicine, University of Michigan, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Drive, Lobby A, Ann Arbor, MI 48106, USA
    Expert Rev Cardiovasc Ther 6:619-22. 2008
    ..It was attended by nearly 30,000 participants from around the world. The conference was highlighted by the presentation of 13 late-breaking clinical trials and 13 late-breaking abstracts...
  8. ncbi request reprint Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, Chicago, IL, USA
    Am Heart J 151:556-63. 2006
    ..Extending statin therapy to patients with low levels of HDL-C but with LDL-C levels below target may have benefits for cardiovascular disease reduction in these patients...
  9. pmc Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial
    Michael Davidson
    Radiant Research, Chicago, IL 60610, USA
    Cardiovasc Drugs Ther 26:349-58. 2012
    ....
  10. doi request reprint Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production
    Robert S Rosenson
    Department of Medicine, SUNY Downstate, Brooklyn, NY 11203, USA
    Cardiovasc Drugs Ther 23:289-94. 2009
    ..Despite these putative mechanisms, amlodipine is equally efficacious as other therapies in reducing cardiovascular events...
  11. ncbi request reprint Assessing risk across the spectrum of patients with the metabolic syndrome
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Am J Cardiol 96:8E-10E. 2005
    ..Risk assessment models for patients with the metabolic syndrome should consider inclusion of LDL particle number, inflammatory markers, and levels of plasminogen activator inhibitor-1...
  12. ncbi request reprint Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia
    Robert S Rosenson
    Department of Medicine, Division of Cardiology, Preventive Cardiology Center, The Feinberg School of Medicine, Northwestern University, 201 East Huron Street, Galter Pavilion, Suite 11 120, Chicago, IL 60611, USA
    Atherosclerosis 177:77-81. 2004
    ..048). A high level of sTNFRSF1B is a strong marker of the pro-inflammatory state in this sample of male ADL subjects...
  13. ncbi request reprint Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Galter Pavilion 11 120, 201 East Huron Street, Chicago, IL 60611, USA
    Curr Opin Cardiol 20:313-7. 2005
    ..Discuss the contribution of low-density lipoprotein subclass abnormalities to cardiovascular risk among individuals with low high-density lipoprotein cholesterol levels...
  14. ncbi request reprint Antiatherothrombotic effects of nicotinic acid
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 East Huron Street, Galter Pavilion 11 120, Chicago, IL 60612, USA
    Atherosclerosis 171:87-96. 2003
    ..By preserving glycolysis during periods of ischemia and improving subendocardial blood flow during reperfusion, niacin can improve the functional recovery of the myocardium...
  15. ncbi request reprint Low HDL-C: a secondary target of dyslipidemia therapy
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, Chicago, Ill 60611, USA r rosenson northwestern edu
    Am J Med 118:1067-77. 2005
    ..Although lowering LDL-C remains the primary target of lipid-modifying therapy, dyslipidemia therapies that are efficacious for both LDL-C reduction and raising HDL-C might offer further improvements in CHD risk reduction...
  16. ncbi request reprint Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 East Huron Street, Galter Pavilion, Chicago, IL 60611, U S A
    Clin Sci (Lond) 106:215-7. 2004
    ..In contrast with the known effects of oxidized LDL on gene activation of ICAM-1 and VCAM-1, lag times did not correlate with sICAM-1 and sVCAM-1. Statin therapy improved lag times, but has no effect on sICAM-1 or sVCAM-1 levels...
  17. ncbi request reprint An assessment of statin safety by muscle experts
    Paul D Thompson
    Division of Cardiology, Hartford Hospital, Hartford, Connecticut 06102, USA
    Am J Cardiol 97:69C-76C. 2006
    ..The panel was composed of a clinical cardiologist, an exercise physiologist and skeletal muscle expert, and an expert in preventive cardiology who also examined skeletal muscle complications of statin use...
  18. ncbi request reprint Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day
    Robert S Rosenson
    Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Am J Cardiol 91:878-81. 2003
  19. ncbi request reprint HDL-C and the diabetic patient: target for therapeutic intervention?
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 East Huron Street, Galter Pavilion Suite 11 120, Chicago, IL 60611, USA
    Diabetes Res Clin Pract 68:S36-42. 2005
    ..Selecting an agent that will increase HDL-C levels, as well as lowering LDL-C levels, may be particularly beneficial in the treatment of patients with the metabolic syndrome and type 2 diabetes...
  20. doi request reprint Novel targets that affect high-density lipoprotein metabolism: the next frontier
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 104:52E-7E. 2009
    ..This article reviews current options for the therapeutic management of HDL cholesterol, including discussion of novel agents aimed at reducing cardiovascular disease risk in patients with low levels of HDL cholesterol...
  21. ncbi request reprint New approaches in the intensive management of cardiovascular risk in the metabolic syndrome
    Robert S Rosenson
    Department of Medicine, Northwestern University, Feinberg School of Medicine, USA
    Curr Probl Cardiol 30:241-79. 2005
    ..A multifaceted approach to risk factor management for the metabolic syndrome will have benefits for prevention of type 2 diabetes and cardiovascular disease...
  22. ncbi request reprint Current overview of statin-induced myopathy
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Med 116:408-16. 2004
    ..Drug-drug interactions may be avoided by selecting a statin that does not share the same metabolic pathway...
  23. ncbi request reprint Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 E Huron Street, Galter Pavilion, Suite 11 120, Chicago, IL 60611, USA
    Atherosclerosis 173:1-12. 2004
    ..It may be that the ability of statins to limit the oxidation of LDL contributes to their effectiveness at preventing atherosclerotic disease...
  24. ncbi request reprint Modulating atherosclerosis through inhibition or blockade of angiotensin
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Clin Cardiol 26:305-11. 2003
    ..This article reviews some of the biologic mechanisms whereby ACE inhibitors and ARBs may modulate atherosclerosis...
  25. ncbi request reprint Utility of inflammatory markers in the management of coronary artery disease
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 92:10i-8i. 2003
    ..Some fibrates decrease fibrinogen levels and hs-CRP. Statin therapy either reduces the CAD risk associated with system inflammation or lowers circulating levels of hs-CRP...
  26. ncbi request reprint Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, IL 60611, USA
    Expert Rev Cardiovasc Ther 1:495-505. 2003
    ..Rosuvastatin is well tolerated, with a safety profile comparable with that of other currently available statins...
  27. ncbi request reprint Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Departments of Medicine and Preventive Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Curr Opin Cardiol 19:480-7. 2004
    ..This article reviews evidence that treatments directed at the individual components of the metabolic syndrome will delay the progression to type 2 diabetes and will reduce the incidence of cardiovascular disease...
  28. ncbi request reprint The rationale for combination therapy
    Robert S Rosenson
    Department of Medicine and Preventive Medicine, Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 90:2K-7K. 2002
    ..This article reviews the rationale for the use of combination therapy in the treatment of dyslipidemia, highlighting management strategies...
  29. ncbi request reprint Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA
    Am J Cardiol 90:89-94. 2002
    ..01) in the placebo group. These results indicate that levels of various lipoprotein subclasses may provide useful information on CAD risk even if levels of traditional risk factors are known...
  30. ncbi request reprint Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity
    Robert S Rosenson
    Lipoprotein and Hemorheology Research Facility, Section of Cardiology, Department of Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
    Atherosclerosis 161:433-9. 2002
    ..This study supports an additional mechanism whereby triglycerides may contribute to cardiovascular risk...
  31. ncbi request reprint Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial
    Scott M Grundy
    The University of Texas Southwestern Medical Center, Room Y3206, 5323 Harry Hines Blvd, Dallas, TX 75390 9052
    Arch Intern Med 162:1568-76. 2002
    ..We evaluated the efficacy and safety of once-daily extended-release (ER) niacin in patients with diabetic dyslipidemia...
  32. ncbi request reprint Effect of methyl testosterone administration on plasma viscosity in postmenopausal women
    Shehzad Basaria
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Clin Endocrinol (Oxf) 57:209-14. 2002
    ..Recently, there has been a growing interest in the treatment of postmenopausal women with androgens. However, no data are available on plasma viscosity and fibrinogen levels in postmenopausal women on combined oestrogen/androgen therapy...
  33. doi request reprint Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI 48106 0636, USA
    Am Heart J 155:499.e9-16. 2008
    ..Fenofibrate reduces Lp-PLA2 mass; however, it remains unknown whether the anti-inflammatory effects of fenofibrate are related to changes in LDL subclasses...
  34. doi request reprint Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Domino s Farms, 24 Frank Lloyd Wright Drive, Lobby A, Ann Arbor, MI 48106 0736, USA
    Atherosclerosis 198:381-8. 2008
    ..To examine the effects of fenofibrate (160mg/d) therapy on fasting and postprandial cytokine production in subjects with metabolic syndrome and hypertriglyceridemia...
  35. ncbi request reprint Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus
    Robert S Rosenson
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48106 0363, USA
    Am J Cardiol 99:96B-104B. 2007
    ..Future studies of PPAR-gamma agonists or dual PPAR-alpha/gamma agonists will require further delineation of the risk profile to avoid adverse outcomes in susceptible patients...
  36. ncbi request reprint Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study
    Lawrence A Leiter
    Division of Endocrinology and Metabolism, St Michael s Hospital, University of Toronto, Toronto, Canada
    Atherosclerosis 194:e154-64. 2007
    ..Rosuvastatin may therefore improve LDL-C goal achievement in high-risk patients with hypercholesterolemia...
  37. ncbi request reprint Field of confusion: future prospects for fibrate therapy in cardiovascular disease
    Robert S Rosenson
    Curr Atheroscler Rep 8:219-22. 2006
  38. ncbi request reprint Statin therapy: new therapy for cardiac microvascular dysfunction
    Robert S Rosenson
    Eur Heart J 24:1993-4. 2003
  39. ncbi request reprint Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial
    James D Otvos
    Department of Biochemistry, North Carolina State University, Raleigh, NC, USA
    Atherosclerosis 160:41-8. 2002
    ....